siRNA therapy - Capricor Therapeutics
Alternative Names: Exosomes loaded with siRNA - CapricorLatest Information Update: 08 Dec 2023
At a glance
- Originator Capricor Therapeutics
- Class Antineoplastics; Exosome therapies; Small interfering RNA
- Mechanism of Action Ribonucleotide reductase M2 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 22 Nov 2023 siRNA therapy - Capricor is available for licensing as of 22 Nov 2023. https://www.capricor.com/our-science/strategic-partnerships (Capricor Therapeutics website; November 2023)
- 14 Nov 2023 Preclinical trials in Ovarian cancer in USA (Parenteral) prior to November 2023
- 14 Nov 2023 Pharmacodynamics data from a preclinical trial in Ovarian cancer released by Capricor Therpaeutics